Karuna Therapeutics Inc. (KRTX) PT Raised to $165 at RBC Capital, Sees Underappreciated De-Risking

March 1, 2021 6:50 AM EST
Get Alerts KRTX Hot Sheet
Price: $108.68 -3.48%

Rating Summary:
    12 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 20 | New: 68
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

RBC Capital analyst Brian Abrahams raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $165.00 (from $160.00) while maintaining a Outperform rating.

The analyst comments "Late last week, KRTX reported preliminary qualitative data from its ph.Ib study of lead drug KarXT in elderly healthy volunteers. We performed a deep dive into the results and came away increasingly confident that (1) safety/tolerability and (2) efficacy have now been appreciably de-risked to a larger degree than the early DRP development stage would imply, and (3) 3x/day dosing is not a major concern. With shares -6% since the announcement, we believe the Street is overlooking the growing viability of a potential future $1.5B annual KarXT revenue stream in elderly psychotic disorders. Increase price target to $165 (from $160) and remain buyers."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

RBC Capital